Drugs / GIP(1-42)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable1 trial · 1 met primary | ||||||
| — | NCT02747472 | Apr → Jul 2016 | glucose metabolism disease | University Hospital, Gentofte, Copenhagen | Completed | Met primary |
| Comparator or background therapy2 trials | ||||||
| — | NCT06194955 Comparator | Jan 2023 → Dec 2025 | hyperproglucagonemia | University of Copenhagen | Completed | No outcome recorded |
| — | NCT03526289 Comparator | Nov 2017 → Oct 2018 | type 2 diabetes mellitus | University Hospital, Gentofte, Copenhagen | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GIP1-42 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03526289 ↗ |
| Action | Activate | “GIP receptor agonist” NCT02747472 ↗ |
| Route | Intravenous | “concomitant iv infusion of GIP\[1-42\]” NCT02747472 ↗ |